Arbutus Biopharma Corp (ABUS)
Healthcare
Biotechnology
4.30 $
-1.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Arbutus Biopharma Corp (ABUS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 61.4% of the shares are freely tradable; institutional investors hold 71.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
71.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
20.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
61.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
13.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
198Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 13.11 | 25,891,480 | -3.0 | 03/31/2026 |
| Two Seas Capital LP | 9.39 | 18,557,543 | +47.4 | 03/31/2026 |
| Whitefort Capital Management, LP. | 7.56 | 14,930,885 | +11.9 | 03/31/2026 |
| BlackRock Inc | 6.56 | 12,966,946 | -0.7 | 03/31/2026 |
| Vanguard Group Inc | 4.68 | 9,242,437 | +2.8 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.39 | 6,688,911 | +0.0 | 03/31/2026 |
| Rubric Capital Management LP | 3.35 | 6,626,389 | +320.6 | 03/31/2026 |
| State Street Corp | 3.21 | 6,342,510 | +7.4 | 03/31/2026 |
| Barclays PLC | 2.18 | 4,316,095 | +1,110.1 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.44 | 4,811,847 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.